Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Crunch time for multiple-gene tests

    Nature volume 445, pages 354–355 (2007)Cite this article

    Sophisticated new genetic tests face an uncertain future — unless they can win clear-cut approval from regulators, insurers and, most importantly, doctors. Virginia Gewin reports.

    Some say that the test — Oncotype DX, developed by Genomic Health of Redwood City in California — is a portent for the long-awaited and much-hyped era of 'personalized medicine', in which therapies are fine-tuned to meet patient needs.

    This is a preview of subscription content, access via your institution

    Access options

    Buy article

    Get time limited or full article access on ReadCube.

    $32.00

    Buy

    All prices are NET prices.

    Related links

    Related links

    Related links in Nature Research

    Opinion: The US Food and Drug Administration perspective on cancer biomarker development

    A regulatory perspective on in vitro diagnostics

    New-wave diagnostics

    Three barriers to innovative diagnostics

    Related external links

    FDA draft guidance on diagnostic assays

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Crunch time for multiple-gene tests. Nature 445, 354–355 (2007). https://doi.org/10.1038/445354a

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1038/445354a

    This article is cited by

    Search

    Advanced search

    Quick links

    Nature Briefing

    Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

    Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing